

HEMOGLOBIN C_{HARLEM}: A SICKLING VARIANT CONTAINING AMINO ACID SUBSTITUTIONS
IN TWO RESIDUES OF THE β -POLYPEPTIDE CHAIN

Robert M. Bookchin¹, Ronald L. Nagel, Helen M. Ranney² and Alan S. Jacobs

Department of Medicine and Heredity Clinic
Albert Einstein College of Medicine
New York, New York 10461

Received March 14, 1966

Many of the variants of human hemoglobin have been shown to result from a single amino acid substitution in each of the pair of like polypeptide chains in the tetrameric hemoglobin. This report describes an abnormal hemoglobin, designated hemoglobin C_{Harlem}, which has been found to contain two amino acid substitutions in the β -polypeptide chains; one substitution is probably that of hemoglobin S, $\beta^6 \text{ val}$, but $\beta^7 \text{ val}$ has not been ruled out. The second is a substitution in peptide $\beta\text{Tp IX}$, in which asparagine replaces aspartic acid at $\beta 73$. Such an abnormal hemoglobin could have its origin in a second mutation in a β chain which already carried a single mutation in either the 6 or 73 residue, or could result from crossing over in an individual who was doubly heterozygous for hemoglobin S and, for example, for a hemoglobin with the structure $\alpha_2^A \beta_2^{73 \text{ asn}}$.

Hemoglobin C_{Harlem} was observed in 7 members of an American Negro family referred to us by Miss Mary H. McKenna of the laboratories of Harlem Hospital, who observed the association of what appeared to be hemoglobin C trait with erythrocyte sickling. The hemoglobin migrated slightly anodal to hemoglobin C at pH 8.6, and amounted to 40 per cent of the hemoglobin in each of the affected members of the family. Isolated hemoglobin C_{Harlem} exhibited an

-
1. Trainee, United States Public Health Service Training Grant NIH T1 AM 5435
 2. Career Scientist of the Health Research Council of the City of New York, Contract I-392

oxygen equilibrium like that of hemoglobin A, and in high concentration, like hemoglobin S, gelled on deoxygenation with subsequent liquefaction on cooling. Both deoxyhemoglobins C_{Harlem} and S are relatively insoluble as compared with hemoglobin A: by the method of Itano (1953), the solubility of deoxyhemoglobin C_{Harlem} was 0.17 grams per liter and that of deoxyhemoglobin 0.12 grams per liter in 2.24M phosphate buffer at pH 6.8, while deoxyhemoglobin A and the oxy-form of each show no precipitate under these conditions.

Recombination experiments carried out at pH 4.7 (Itano and Singer, 1958) disclosed new species on recombination of hemoglobin C_{Harlem} with hemoglobin I (an α chain abnormality) but none on recombination with hemoglobin C, a β chain abnormality. The recovery of new species, corresponding to $\alpha_2^A \beta_2^A$ and $\alpha^I \beta^{C_{\text{Harlem}}}$ indicated that the abnormality was in the β chain of hemoglobin C_{Harlem} .

Hemoglobin C_{Harlem} was purified on DEAE-cellulose (Huisman and Dozy, 1962) and the β chains were isolated by a modification of the method of Bucci and Fronticelli (1965), in which PMB* was added to the hemoglobin at pH 5.8 and the α and β chains subsequently separated by starch block electrophoresis in veronal at pH 8.6. Peptide maps of the tryptic digests of the isolated β chains were made by Baglioni's modification (1961) of the method of Ingram (1958). Comparison of these peptide maps with those prepared from isolated normal β chains (Fig. 1) showed the following differences: (1) $\beta\text{Tp I}$ (designated according to numbering system of Gerald and Ingram, 1961) was missing and a new peptide with a greater R_f moved further toward the cathode. (2) $\beta\text{Tp IX}$ and $\beta\text{Tp VIII-IX}$ were missing and two other new peptides were cathodal to the $\beta\text{Tp IX}$ and $\beta\text{Tp VIII-IX}$ positions. The first abnormal peptide was in the position of $\beta\text{Tp I}$ of hemoglobin S. Following acid hydrolysis of this abnormal peptide amino acid analysis (Beckman model 120B amino acid analyzer) demonstrated one glutamic acid and two valine residues compared

* PMB = parahydroxymercuribenzoate




Figure 1. Tracings of the tryptic peptide maps of β^{CHarlem} globin and β^{A} globin. Peptides are numbered according to Ingram (1958). Note that peptide 4 ($\beta\text{Tp I}$) of hemoglobin CHarlem migrates cathodal to the normal position of $\beta\text{Tp I}$ with a greater R_f , in the position of $\beta^{\text{S}}\text{Tp I}$, and that peptides 6 ($\beta\text{Tp IX}$) and b ($\beta\text{Tp VIII-IX}$) of hemoglobin CHarlem are cathodal to the position of these peptides of hemoglobin A. In the fingerprint of β^{A} globin peptide 22 did not separate from peptide 21.

with two glutamic and one valine residue in hemoglobin A (Table 1). The sequence of $\beta^A\text{Tp I}$ is as follows (Goldstein et al., 1963):

val-his-leu-thr-pro-glu-glu-lys-
1 2 3 4 5 6 7 8

Thus a substitution of valine for glutamic acid apparently occurred in position 6 or 7 of the β chain.

Table 1

Molar ratios of amino-acid residues after acid hydrolysis of β tryptic peptides I from hemoglobin A and hemoglobin C_{Harlem} .

Residues	$\beta^A\text{Tp I}$	$\beta^{C_{\text{HTp}}} \text{I}$
Lys	1.0	1.0
His	0.9	0.7
Thr	1.0	0.9
Glu	1.9	1.2
Pro	1.2	1.1
Val	0.9	1.8
Leu	1.3	1.0

$\beta\text{Tp VIII}$ is free lysine from position 66 which is variably split during tryptic digestion from the 67 valine residue of $\beta\text{Tp IX}$, resulting in the two peptides, $\beta\text{Tp IX}$ and $\beta\text{Tp VIII-IX}$:

$\begin{array}{cccccccccccccccccccccccc} \text{-lys-} & \text{-lys-} & & \text{val-leu-gly-ala-phe-ser-asp-gly-leu-ala-his-leu-asp-asn-leu-lys-} \\ 65 & 66 & 67 & 68 & 69 & 70 & 71 & 72 & 73 & 74 & 75 & 76 & 77 & 78 & 79 & 80 & 81 & 82 \\ \beta\text{Tp VIII} & & & & & & & & & \beta\text{Tp IX} & & & & & & & & \end{array}$

Similar analysis of the other two abnormal peptides (Table 2) demonstrated no difference from their normal counterparts, $\beta^A\text{Tp IX}$ and $\beta^A\text{Tp VIII-IX}$, but their electrophoretic mobilities indicated that each abnormal peptide had a greater positive charge than the corresponding peptide from hemoglobin A. These findings could be explained only by the replacement of one of the two aspartic acid residues by an asparaginy1, which would be converted by acid hydrolysis into aspartic acid. This situation was encountered previously with hemoglobin G_{Accra} (Lehmann et al., 1964) in which the aspartic acid residue at $\beta 79$ was replaced by asparagine. The published fingerprint of the tryptic digest of hemoglobin G_{Accra} shows $\beta\text{Tp IX}$ having moved apparently to the same position as $\beta\text{Tp IX}$ of hemoglobin C_{Harlem} . Either of the two

aspartic acid residues in β Tp IX, at positions 73 or 79, could be replaced by asparagine in hemoglobin C_{Harlem}. To distinguish between these two

Table 2

Molar ratios of amino-acid residues after acid hydrolysis of β tryptic peptides IX and VIII-IX from hemoglobin A and hemoglobin C_{Harlem}.

Residues	β^A Tp IX	$\beta^{C_{Harlem}}$ Tp IX	β^A Tp VIII-IX	$\beta^{C_{Harlem}}$ Tp VIII-IX
Lys	1.0	1.0	2.2	1.8
His	0.9	0.9	1.0	0.8
Asp	2.9	3.3	3.0	3.0
Ser	1.2	1.0	1.4	1.3
Gly	2.2	2.2	2.1	2.2
Ala	2.1	2.1	2.1	2.2
Val	1.1	0.9	0.7	0.7
Leu	3.7	4.0	4.2	4.0
Phe	0.9	0.9	1.3	1.0

possibilities the normal and abnormal peptides β Tp IX were eluted with 10 per cent pyridine, lyophilized, and digested with 0.01 per cent pepsin at 25°C for 20 hours as described by Goldstein et al. (1963). Fingerprints of the resulting digests revealed an anodally migrating peptide from β^A Tp IX which was absent in the digest of $\beta^{C_{Harlem}}$ Tp IX; the latter contained a new peptide migrating in the neutral zone. Amino acid analyses of these two peptides yielded equimolar quantities of phe, ser, asp, gly and leu from β^A Tp IX and phe, ser, asp and gly from $\beta^{C_{Harlem}}$ Tp IX, apparently representing positions 71-75 and 71-74 of the respective β Tp IX peptides. The difference in leucine between these two peptides is consistent with the products of its pepsin digestion (Goldstein et al., 1963) and does not account for their different electrophoretic mobilities. These preliminary results suggest that the aspartic acid residue at β 73 is replaced by asparagine.

The occurrence of two substitutions in a single polypeptide chain of hemoglobin has not been previously observed; however the high frequency of hemoglobins S and C in persons of African descent increases the probability of encountering a second amino-acid substitution in these mutant β -polypeptide chains. The substitutions in hemoglobin C_{Harlem} (valine for glutamic, asparagine for aspartic) conform to the expected results of substitution of a

single base in the triplet code of messenger RNA as do all the known substitutions in hemoglobin variants (Beale and Lehmann, 1965).

Hemoglobin C_{Harlem} could have originated when a second mutation occurred in an individual with hemoglobin S (such individuals may constitute 40 per cent of the population in certain areas of East Africa), or by homologous crossing over within the β chain locus between determinants for $\beta 6$ and $\beta 73$. The greater distance between these positions on the β chain might favor crossing over between the two, as compared with crossing over between sites for hemoglobin S and certain other β abnormalities, e.g. $\beta 7$ (hemoglobin G_{San Jose}), or $\beta 16$ (hemoglobin J_{Baltimore}).

In tertiary structure, residue $\beta 73$ is spatially closer to $\beta 6$ than the residue numbers would imply. From the recent model of Perutz (1965), $\beta 73$ occupies the 17th position of the E helix which is near the N-terminal portion of the β chain. While hemoglobin C_{Harlem} retains many properties of hemoglobin S, viz. sickling, gelation of the hemolysate on deoxygenation with liquefaction on cooling, and relative insolubility of the deoxy form, a detailed comparison of these properties reveals differences which must result from the second substitution in hemoglobin C_{Harlem}. An account of these studies and of the clinical findings associated with hemoglobin C_{Harlem} will be part of a separate report.

Acknowledgements

Supported by research grants (NI AM 04502 and RO1 AM 0924) and a training grant (T1 AM 5435) from the National Institutes of Health, United States Public Health Service.

References

- Baglioni, C. *Biochim. Biophys. Acta* 48, 392 (1961).
Beale, D. and Lehmann, H. *Nature* 207, 259 (1965).
Bucci, E. and Fronticelli, C. *J. Biol. Chem.* 240, PC 551 (1965).
Clegg, J.B., Naughton, M.A. and Weatherall, D.J. *Nature* 207, 945 (1965).
Gerald, P.S. and Ingram, V.M. *J. Biol. Chem.* 236, 2155 (1961).
Goldstein, J., Konigsberg, W. and Hill, R.J. *J. Biol. Chem.* 238, 2016 (1963).
Huisman, T.H.J. and Dozy, A.M. *J. Chromat.* 7, 180 (1962).
Ingram, V.M. *Biochim. Biophys. Acta* 28, 539 (1958).
Itano, H.A. *Arch. Biochem.* 47, 148 (1953).
Itano, H.A. and Singer, S.J. *Proc. Natl. Acad. Sci. U.S.*, 44, 522 (1958).
Lehmann, H., Beale, D. and Boi-Doku, F.S. *Nature* 203, 363 (1964).